WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substan...
How does the sentiment rating of 80 translate into market expectations, and does it reflect a bullish or cautious sentiment among investors?
What are the key risks associated with scaling the automated continuous production platform, including technical, regulatory, and operational risks?
Will this development enable new partnership or licensing opportunities with pharmaceutical companies, and how could that affect future revenue streams?
10 days ago